Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Human Metabolome Technologies, Inc. ( (JP:6090) ).
Human Metabolome Technologies, Inc., listed on the Tokyo Stock Exchange Standard Market, operates in the metabolomics field, providing analytical and measurement technologies to research and healthcare clients. The company targets specialized life science markets where high-precision metabolic profiling supports drug discovery, diagnostics, and related applications.
For the six months ended December 2025, the company reported a 3.7% year-on-year decline in net sales to ¥659 million and a sharp fall in operating profit by 55.2% to ¥46 million, with profit attributable to owners of parent halving to ¥43 million. Despite weaker earnings, the balance sheet remained strong, with total assets at ¥2,137 million, a high capital adequacy ratio of 84.6%, and stable net assets of ¥1,807 million, although no first-quarter dividend was declared for the June 2026 fiscal year.
The most recent analyst rating on (JP:6090) stock is a Hold with a Yen758.00 price target. To see the full list of analyst forecasts on Human Metabolome Technologies, Inc. stock, see the JP:6090 Stock Forecast page.
More about Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. is a Japan-based general business company listed on the Tokyo Stock Exchange Standard Market. The firm operates in metabolomics-related services and technologies, focusing on analytical solutions that support life science and healthcare research, with a niche position in advanced biochemical measurement and data analysis markets.
Average Trading Volume: 10,070
Technical Sentiment Signal: Buy
Current Market Cap: Yen4.12B
For a thorough assessment of 6090 stock, go to TipRanks’ Stock Analysis page.